Cyclerion Therapeutics
NASDAQ: CYCNCambridge, US · Founded 2018 · Massachusetts corporation · 3 known investors
Find your way into Cyclerion Therapeutics
49 people in our graph share verified history with the Cyclerion Therapeutics team — schools, employers, funds. One of them is your warm intro.
John McKearnunlockedknows Mark G. Currie · together at Searle (overlapped)
×7knows the team · via Antag Therapeutics
knows the team · via Ironwood Pharmaceuticals
×2knows the team · via University of South Alabama
knows the team · via Wake Forest University School of Medicine
Cyclerion is a biopharmaceutical company developing therapeutics for neuropsychiatric diseases, with a lead candidate (CYC-126) for treatment-resistant depression that pairs anesthetic agents with a personalized biofeedback-driven device. It targets patients, providers, and health systems seeking individualized mental health treatment.
Founders & leadership
WH
William HuyettExecutive
MG
OI
Ole IsacsonNamed on SEC filing
SL
Stephanie LovellNamed on SEC filing
MF
Marsha FanucciNamed on SEC filing
GC
George ConradesNamed on SEC filing
KC
Kevin ChurchwellNamed on SEC filing
PM
Peter M. HechtNamed on SEC filing
MM
Michael MendelsohnNamed on SEC filing
Board
TM
Terrance McGuireBoard director
AS
Investors · 3
Reported raises · per SEC filings
Form D private placements$222.3M disclosed across 4 rounds · 2019–2023
▶$5MraisedMay 2023 · 1 investors · PharmaceuticalsRule 506(b)
▶$5MraisedMay 2023 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Errol De SouzaDirector
- Steven HymanDirector
- Terrance McGuireDirector
- Peter M. HechtDirector, Executive Officer
- Anjeza GjinoExecutive Officer
- Cheryl GaultExecutive Officer
- Ole IsacsonDirector
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- May 2023
- Incorporated
- Corporation, Massachusetts, 2018
- Federal exemptions
- 06b
▶$18MraisedJun 2021 · 7 investors · PharmaceuticalsRule 506(b)
▶$18MraisedJun 2021 · 7 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Stephanie LovellDirector
- Errol De SouzaDirector
- Kevin ChurchwellDirector
- Peter M. HechtExecutive Officer, Director
- Cheryl GaultExecutive Officer
- Terrance McGuireDirector
- George ConradesDirector
- Michael MendelsohnDirector
- Marsha FanucciDirector
- Anjeza GjinoExecutive Officer
- Ole IsacsonDirector
- Andreas BuschExecutive Officer
- Offering amount
- $18M
- Amount sold
- $18M
- First sale
- Jun 2021
- Incorporated
- Corporation, Massachusetts, 2018
- Federal exemptions
- 06b
▶$24.3MraisedAug 2020 · 2 investors · PharmaceuticalsRule 506(b)
▶$24.3MraisedAug 2020 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Kevin ChurchwellDirector
- Terrance McGuireDirector
- Peter M. HechtExecutive Officer, Director
- Marsha FanucciDirector
- Ole IsacsonDirector
- Stephanie LovellDirector
- Amy SchulmanDirector
- George ConradesDirector
- William HuyettExecutive Officer
- Andreas E. BuschExecutive Officer
- Michael MendelsohnDirector
- Mark G. CurrieExecutive Officer
- Offering amount
- $24.3M
- Amount sold
- $24.3M
- First sale
- Jul 2020
- Incorporated
- Corporation, Massachusetts, 2018
- Federal exemptions
- 06b
▶$175MraisedApr 2019 · 49 investors · PharmaceuticalsRule 506(b)
▶$175MraisedApr 2019 · 49 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Ole IsacsonDirector
- Stephanie LovellDirector
- Terrance McGuireDirector
- Amy SchulmanDirector
- Marsha FanucciDirector
- George ConradesDirector
- Kevin ChurchwellDirector
- William HuyettExecutive Officer
- Mark G. CurrieExecutive Officer
- Peter M. HechtExecutive Officer, Director
- Michael MendelsohnDirector
- Offering amount
- $175M
- Amount sold
- $175M
- Sales commissions
- $10.2M
- Placement agents
- J.P. Morgan Securities LLC, Credit Suisse Securities (USA) LLC
- First sale
- Apr 2019
- Incorporated
- Corporation, Massachusetts, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapAlexion Pharmaceuticals27 shared keywordsAlexion is a biopharmaceutical company focused on research and development of treatments for rare diseases, serving rare disease patients and their families worldwide.
Robinhood25 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Companies competing with Cyclerion Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Cyclerion Therapeutics do?
- Cyclerion is a biopharmaceutical company developing therapeutics for neuropsychiatric diseases, with a lead candidate (CYC-126) for treatment-resistant depression that pairs anesthetic agents with a personalized biofeedback-driven device. It targets patients, providers, and health systems seeking individualized mental health treatment.
- Who are Cyclerion Therapeutics's investors?
- Cyclerion Therapeutics's investors include Pappas Capital, Invus, Polaris Partners.
- How much funding has Cyclerion Therapeutics raised?
- Cyclerion Therapeutics has disclosed $222.3M raised across 4 rounds.
- Where is Cyclerion Therapeutics headquartered?
- Cyclerion Therapeutics is headquartered in Cambridge, US.